We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+12.33%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.23B
AUM Growth
-$160M
Cap. Flow
-$204M
Cap. Flow %
-3.9%
Top 10 Hldgs %
34.65%
Holding
139
New
8
Increased
26
Reduced
20
Closed
24

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$97.9M
2
UNH icon
UnitedHealth
UNH
+$60M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$51.5M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$37.9M
5
THC icon
Tenet Healthcare
THC
+$26.7M

Top Sells

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$108M
2
ARGX icon
argenx
ARGX
+$94.8M
3
ABBV icon
AbbVie
ABBV
+$80.5M
4
PFE icon
Pfizer
PFE
+$57.8M
5
GH icon
Guardant Health
GH
+$53.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.41%
2 Miscellaneous 1.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARQT icon
51
Arcutis Biotherapeutics
ARQT
$2.97B
$36.4M 0.7%
2,460,108
-339,892
-12% -$5.94M
TELA icon
52
TELA Bio
TELA
$47.6M
$34.8M 0.67%
3,027,542
– –
ALXO icon
53
ALX Oncology
ALXO
$257M
$32.4M 0.62%
2,871,000
– –
KZR
54
DELISTED
Kezar Life Sciences
KZR
$32.3M 0.62%
458,432
+281,262
+159% +$20.9M
PGNY icon
55
Progyny
PGNY
$2.14B
$32.2M 0.62%
1,035,000
-99,053
-9% -$3.58M
VTYX
56
DELISTED
Ventyx Biosciences
VTYX
$30.3M 0.58%
925,000
+700,000
+311% +$20.7M
ALPN
57
DELISTED
Alpine Immune Sciences Inc
ALPN
$30M 0.57%
4,081,592
– –
TVTX icon
58
Travere Therapeutics
TVTX
$5.85B
$26.4M 0.5%
1,253,130
– –
THRD
59
DELISTED
Third Harmonic Bio
THRD
$24.9M 0.48%
5,779,071
– –
RAPT
60
DELISTED
RAPT Therapeutics
RAPT
$24.8M 0.47%
156,384
– –
KNTE
61
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$24.7M 0.47%
4,043,629
– –
CINC
62
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$23.4M 0.45%
1,906,000
+1,591,798
+507% +$37.9M
JBIO
63
Jade Biosciences
JBIO
$1.12B
$22.3M 0.43%
21,701
-1,013
-4% -$735K
HZNP
64
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$19.5M 0.37%
+171,000
New +$14.2M
GRCL
65
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$18.1M 0.35%
7,884,870
– –
ELVN icon
66
Enliven Therapeutics
ELVN
$3.91B
$17.9M 0.34%
1,096,642
– –
GHRS icon
67
GH Research
GHRS
$1.87B
$15.8M 0.3%
1,622,060
– –
RXST icon
68
RxSight
RXST
$236M
$15.2M 0.29%
1,202,833
– –
MRNA icon
69
Moderna
MRNA
$57.7B
$14.8M 0.28%
+82,550
New +$13.5M
IOVA icon
70
Iovance Biotherapeutics
IOVA
$4.18B
$12.8M 0.25%
2,007,458
– –
PASG icon
71
Passage Bio
PASG
$15.5M
$12.3M 0.24%
446,600
– –
FUSN
72
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$10.2M 0.19%
3,224,770
– –
DBTX
73
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$10.1M 0.19%
4,945,192
– –
TSVT
74
DELISTED
2seventy bio
TSVT
$9.76M 0.19%
1,041,300
– –
ORIC icon
75
Oric Pharmaceuticals
ORIC
$1.27B
$9.47M 0.18%
1,607,568
-480,000
-23% -$1.62M
1 2
3
4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q4 2022 Portfolio in Review

As of Q4 2022, OrbiMed held 139 positions worth $5.23B, down 3% from $5.39B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed withdrew a net $204M in Q4 2022, closing 24 positions and reducing 20 holdings. Its most notable exit was Tricida, Inc. Common Stock, an estimated $108M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $19.5M.

  • OrbiMed's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 171,000 shares worth $19.5M.
  • OrbiMed added most to Disc Medicine in Q4 2022, an estimated $97.9M increase.
  • OrbiMed's biggest Q4 2022 reduction was argenx, cutting an estimated $94.8M.
  • OrbiMed fully exited Tricida, Inc. Common Stock in Q4 2022, selling an estimated $108M.
  • OrbiMed's ten largest holdings make up 35% of its $5.23B portfolio in Q4 2022.
  • OrbiMed opened 8 new positions and closed 24 in Q4 2022.
  • OrbiMed's portfolio value fell 3% quarter-over-quarter to $5.23B.

Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.